A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene AutoleucelFirst published 18/10/2022 Last updated 03/06/2025 EU PAS number: EUPAS49370StudyOngoing